Palvella Therapeutics (PVLA) 10-K2021 FY Annual report

Filed: 1 Mar 22, 7:40pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: ADC, adhesion, adult, adulthood, aerodynamic, aggrecan, aggressive, aggressively, Ahmed, AKS, ALX, Antengene, anti, archived, arrest, arresting, attenuate, attenuated, attenuation, authoritative, Bavarian, BayLDA, beneficiary, beta, Biden, bioavailability, biodistribution, biometric, biopsy, Biosecurity, bleomycin, BP, bribed, bribing, Bundesdatenschutzgesetz, burden, caliber, cap, caption, cardiac, CCN, CCPA, channel, Chinese, chip, CJEU, clarity, closure, CMP, CMPL, cold, Colorado, conflict, COVID, CPRA, CTGF, cytotoxic, death, Demuth, derogate, derogation, devastating, driver, Duocalin, durable, dysregulated, ECM, elasticity, Energy, epitope, ERS, Esbriet, evacuate, exacerbated, excessive, excitation, exploratory, Facebook, fatal, FCA, fibronectin, FIH, forgotten, FVC, Galecto, gas, gastrointestinal, GenKyoTex, geopolitical, handheld, harbor, healing, heparan, hurt, ID, infection, Inline, intercellular, interstitial, intratracheal, intratracheally, invaded, invasion, IPF, landmark, loading, lockdown, lymphopoietin, magnified, matricellular, matrix, Maximilian, medium, mesh, MHRA, military, Ministry, motility, Mousa, MSI, navigating, NCCN, NIH, nintedanib, Ofev, ophthalmology, opposed, overexpression, overview, pamrevlumab, parenteral, parenterally, PASC, passage, passed, passing, penalty, penetrated, penetrating, phenomenon, picomolar, pirfenidone, Pliant, PRAISE, probationary, proven, quarantine, reframe, reinstated, remodeling, repetitive, Republic, retention, revealing, Russia, scanned, scleroderma, sequelae, setanaxib, sink, slowdown, sodium, SPV, step, stimuli, stromal, sulfate, tasked, TGF, thymic, Tim, Tom, topline, tracer, transcriptional, treprostinil, trust, tyvaso, unanimously, underwent, undisputed, unstable, unutilized, vibrating, Virginia, wavelength, wound, xii, Yuhan

Removed: acceleration, Alligator, AnaptysBio, Aptevo, augmenting, behaved, beneficially, Bioscience, Chairman, deductibility, depository, etokimab, exceeded, expensing, FAP, fibroblast, formal, formally, functioned, GBR, Geraghty, Glenmark, isolated, IZB, mbH, migration, murine, NOL, nonrefundable, observation, origination, pari, passu, PEGylated, practical, Prof, rejection, remediate, remediation, retardation, retrospective, revalued, scFv, taxation, territorial, Treasurer, true

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated PVLA transcripts

PVLA similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATIONS UNDER SECTION 906

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), the undersigned officer of Pieris Pharmaceuticals, Inc., a Nevada corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:

The Annual Report for the year ended December 31, 2021 (the “Form 10-K”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company.


Dated: March 1, 2022	/s/ Thomas Bures
	Thomas Bures
	Title:	Senior VP, Chief Financial Officer and Treasurer
		(principal financial officer)